Journal
CANCER CELL
Volume 28, Issue 1, Pages 11-13Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.06.012
Keywords
-
Categories
Ask authors/readers for more resources
Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available